In a research note released Tuesday, Morgan Stanley analyst Bin Li commented on China Biologic Products CBPO.
Li believes the stock price will rise in absolute terms over the next 60 days. The analyst also believes the stock is undervalued due to investors' limited knowledge of the Chinese plasma market, a lack of offshore plasma names and low liquidity.
Shares of the company are up 14 percent Tuesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in